- Takeda fortifies orexin potential with more Phase 3 dataWith a formidable new competitor set to enter the orexin development race, Takeda is out with new data that it hopes will reinforce market-leading potential. The additional results from Takeda’s…Endpoints · 1mo ago↗ source
- Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummetElicio Therapeutics’ pancreatic cancer vaccine failed to improve outcomes in a mid-stage study, but the company is seeking funds to move ahead to a larger Phase 3 trial anyway. Elicio reported ...Endpoints · 1mo ago↗ source
- Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma dataPlus news about Sanofi, PharmaMar, Jazz, Rhythm Pharmaceuticals, Spyre and Zymeworks 🇨🇳 Another obesity readout from China: Gan & Lee Pharmaceuticals, a China-based insulin specialist, anno…